Moderna, Inc.: all 117 studies
Page 2 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Moderna COVID-19 Vaccine mRNA-1273 Observational Pregnancy Outcome StudyTerminatedNCT04958304
- Long-Term Follow-up Survey of COVID-19 Vaccine After VaccinationCompletedNCT04941144
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy AdultsCompletedNCT04916431Phase 1
- A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaTerminatedNCT04899310Phase 1/2
- A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19CompletedNCT04813796Phase 1
- A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-SeropositiveCompletedNCT04528719Phase 1
- Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior ExposureCompletedNCT04144348Phase 1
- An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)Active, not recruitingNCT03897881Phase 2
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy AdultsCompletedNCT03829384Phase 1
- Open Label Study of mRNA-3704 in Patients With Isolated Methylmalonic AcidemiaWithdrawnNCT03810690Phase 1/2
- Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesCompletedNCT03739931Phase 1
- "The MaP Study": Mapping the Patient Journey in MMA and PACompletedNCT03484767
- Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy AdultsCompletedNCT03392389Phase 1
- Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy AdultsCompletedNCT03382405Phase 1
- Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult SubjectsCompletedNCT03345043Phase 1
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsActive, not recruitingNCT03313778Phase 1
- Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult SubjectsCompletedNCT03076385Phase 1